CELLO Study for Radiologically Isolated Syndrome (RIS)
- Study HIC#:2000029952
- Last Updated:01/01/0001
Do you have a close family member with Multiple Sclerosis (MS)? Have you ever wondered if you are at risk for developing MS? You may be eligible to participate in a research study.
CELLO Study
Radiologically isolated syndrome (RIS) is diagnosed when someone is discovered to have brain MRI abnormalities that look like MS, but they have never had symptoms of MS. Many people diagnosed with RIS ultimately develop MS. The CELLO clinical trial is examining whether shortterm use of ocrelizumab, an immune modulating medication used to treat MS, can prevent MS brain abnormalities and/or MS symptoms from developing in people with RIS.
You may be eligible to participate in the CELLO study if you:
- Have been diagnosed with radiologically isolated syndrome
- Are between age 18 and 40
If you have not been diagnosed with RIS, but are a close family member of someone with MS and would like to participate in the study, we can test you for RIS as part of the study. Testing would involve getting an MRI of the brain. CELLO study participants would complete study visits over 4 years and donate biospecimens including blood, mouth swabs, and spinal fluid. Compensation is provided.
For more information, please visit cellostudy.org or contact MSResearch@yale.edu
- Age18 years - 40 years
- GenderBoth
Contact Us
For more information about this study, including how to volunteer, contact:
MS Research CELLO Study
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Trial Purpose and Description
Do you have a close family member with Multiple Sclerosis (MS)? Have you ever wondered if you are at risk for developing MS? You may be eligible to participate in a research study.
CELLO Study
Radiologically isolated syndrome (RIS) is diagnosed when someone is discovered to have brain MRI abnormalities that look like MS, but they have never had symptoms of MS. Many people diagnosed with RIS ultimately develop MS. The CELLO clinical trial is examining whether shortterm use of ocrelizumab, an immune modulating medication used to treat MS, can prevent MS brain abnormalities and/or MS symptoms from developing in people with RIS.
You may be eligible to participate in the CELLO study if you:
- Have been diagnosed with radiologically isolated syndrome
- Are between age 18 and 40
If you have not been diagnosed with RIS, but are a close family member of someone with MS and would like to participate in the study, we can test you for RIS as part of the study. Testing would involve getting an MRI of the brain. CELLO study participants would complete study visits over 4 years and donate biospecimens including blood, mouth swabs, and spinal fluid. Compensation is provided.
For more information, please visit cellostudy.org or contact MSResearch@yale.edu
Eligibility Criteria
Inclusion Criteria:
- Have been diagnosed with radiologically isolated syndrome
- Are between age 18 and 40
